Categories: News

AVATR VISION XPECTRA Makes Global Debut, AVATR Showcasing Original Design in Munich

MUNICH, Sept. 8, 2025 /PRNewswire/ — AVATR Technology held its “Brilliant New Horizon AVATR Brand Day” at UTOPIA München in Munich, Germany. The world’s first Emotive Intelligent (EI) vision car, AVATR VISION XPECTRA, made its debut, alongside the limited-edition AVATR 012 co-created with Kim Jones, the exclusive custom AVATR 11 Royal Edition, the Urban Luxury SUV AVATR 07, and the Luxury Sports Sedan AVATR 06. These star models formed a new luxury matrix and will also be showcased from September 9 to 14 at the 2025 Munich Auto Show, fully showcasing the brand’s systematic achievements in original design and intelligent technology.

- Advertisement -

The design inspiration for the AVATR VISION XPECTRA stems from the “Power of Natural Energy.” Its exterior is defined by clean, bold lines that convey a powerful yet poised stance, while the interior combines carefully selected materials with cutting-edge technology to create an intelligent, personalized, and immersive space. Chief Design Officer Nader stated, “AVATR VISION XPECTRA is an Emotional Intelligence companion shaped by energy and connected through emotion. Here, every journey becomes a vivid declaration of ‘Emotive Luxury.'”

- Advertisement -

The global debut of AVATR VISION XPECTRA not only represents a new attempt by AVATR in original design but also reflects the brand’s exploration direction centered on the core concept of “Emotive Luxury.” AVATR stated that it will continue to combine original design with intelligent technology to deliver future mobility experiences that surpass expectations and redefine imagination.

- Advertisement -

Photo – https://mma.prnewswire.com/media/2766856/1.jpg
Photo – https://mma.prnewswire.com/media/2766857/2.jpg

- Advertisement -

View original content:https://www.prnewswire.co.uk/news-releases/avatr-vision-xpectra-makes-global-debut-avatr-showcasing-original-design-in-munich-302548767.html

- Advertisement -

Recent Posts

Ocular Therapeutix Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

February 06, 2026 16:01 ET  | Source: Ocular Therapeutix, Inc. BEDFORD, Mass., Feb. 06, 2026…

6 hours ago

NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

February 06, 2026 16:01 ET  | Source: NewAmsterdam Pharma N.V. NAARDEN, The Netherlands and MIAMI,…

6 hours ago

Novartis breaks ground on new global Biomedical Research center in San Diego to accelerate drug discovery

New facility will enable end‑to‑end discovery across key disease areas and technology platforms, joining existing…

6 hours ago

The Ministry of Finance and the International Monetary Fund to launch tomorrow the second edition of the AlUla Conference for Emerging Market Economies

AlUla, Saudi Arabia, Feb. 7, 2026 /PRNewswire/ -- The second edition of the AlUla Conference…

6 hours ago

Roches fenebrutinib is the first investigational medicine in over a decade that reduces disability progression in primary progressive multiple sclerosis (PPMS)

Late-breaking Phase III FENtrepid results presented at ACTRIMS show investigational fenebrutinib met its primary endpoint…

6 hours ago

Lexicon Announces Closing of Approximately $94.6 Million Public Offering and Concurrent Private Placement

February 06, 2026 17:17 ET  | Source: Lexicon Pharmaceuticals, Inc. THE WOODLANDS, Texas, Feb. 06,…

6 hours ago